Julie Trulson
Vice President, Head of CMC
San Jose, California, United States
Professional Overview
Julie Trulson is an accomplished biopharmaceutical executive with over 20 years of experience in process development and manufacturing. As the Vice President and Head of CMC at Asher Biotherapeutics, she is responsible for overseeing all chemistry, manufacturing, and controls (CMC) activities to support the company's pipeline of innovative biotherapeutics.
Experience Summary
Current Role
In her current role at Asher Biotherapeutics, Julie is leading the CMC team in the successful development and scale-up of several novel biological drug candidates. She has implemented robust quality systems and driven operational efficiencies to ensure timely and compliant delivery of clinical trial materials. Under her leadership, the CMC function has become a strategic partner, enabling the advancement of Asher's pipeline and contributing to the company's overall success.
Career Progression
Prior to joining Asher, Julie held progressive leadership positions in process development and manufacturing at leading biopharmaceutical companies, including Allogene Therapeutics, OncoMed Pharmaceuticals, Boehringer Ingelheim, Amgen, and Abgenix. She has a proven track record of delivering innovative solutions, driving cross-functional collaboration, and achieving key regulatory milestones.
Academic Background
Julie holds a Ph.D. in Chemical Engineering from the University of California, Berkeley, with a focus on bioprocess engineering. She has also completed executive leadership training programs at Stanford University and the Massachusetts Institute of Technology.
Areas of Expertise
- Biopharmaceutical process development and scale-up
- Upstream and downstream process optimization
- Analytical method development and validation
- Regulatory affairs and quality assurance
- Facility design and technology transfer
- Team leadership and change management
Professional Impact
Julie's contributions have been recognized through multiple industry awards, including the prestigious Pharma Manufacturing Excellence Award for her work in implementing novel continuous processing technologies. She is an active member of the Parenteral Drug Association (PDA) and the International Society for Pharmaceutical Engineering (ISPE), where she regularly shares her expertise through conference presentations and publications.
Conclusion
With her extensive industry experience, technical expertise, and proven leadership abilities, Julie Trulson is a valuable asset to Asher Biotherapeutics. Her strategic vision and operational excellence have positioned the company for long-term success in the development and commercialization of innovative biotherapeutics.
